Core A: Administrative Core

摘要 新发病毒（EV）不断从人畜共患病宿主中产生，威胁全球健康和经济稳定， 持续的COVID 19大流行已经感染了超过2.2亿人，造成超过4.8 全球百万人死亡。行政和管理核心（Adman Core A） 它的结构是管理和协调五个项目（PR 1 -5）开展的所有活动， 三个科学核心（核心B-D）位于快速发展的抗病毒药物开发计划中 AViDD中心（READDI-AC）。核心A有五个具体目标，提供：（目标1）果断的领导， 行政和财务监督;（目标2）项目与核心、共同 合作伙伴、NIH和外部合作者/顾问;（目标3）整个中心的数据管理和安全; (Aim 4）管理结构需要审查研究进展，发现问题，定期审查 目标5）试点和指导奖励管理。 此外，Adman Core A将通过开放共享， 试剂、工具、测定法和模型，催化针对新兴病毒的稳健的体外和体内测定法。广告人 核心A管理着一支多元化的学术和行业合作伙伴团队，在抗病毒药物方面拥有深厚的专业知识 来自多个领域的发现，包括病毒学家，生物化学家，结构生物学家，酶学学家， 药理学家、建模师和药物化学家。重要的是，Adman Core A还与制药公司合作， 领导者，特别是武田、强生、Chimerix和Pardes Biosciences，他们贡献了实物资源、分析， 化学资产、化学、专业知识和领导力。该计划采取了创新的方法， 发展，包括由结构基因组学联盟推动的早期开放科学平台， 但随后过渡到鼓励为preIND制定的化学资产的知识产权保护 和IND赋能研究。通过利用我们的企业和学术界的资产和资源， Adman Core A的总体目标是将至少2种DAA药物推进到IND前会议的里程碑 与FDA

ABSTRACT Emerging viruses (EV) constantly arise from zoonotic reservoirs to threaten global health and economic stability, illustrated by the ongoing COVID19 pandemic that has infected over 220 million people and caused over 4.8 million deaths worldwide. The Administrative and Management Core (Adman Core A) is specifically responsive to this RFA and is structured to manage and coordinate all activities conducted by the five projects (PR1-5) and three scientific cores (Cores B-D) housed within the Rapidly Emerging Antiviral Drug Development Initiatives AViDD Center (READDI-AC). Core A has five specific aims that provide: (Aim 1) decisive leadership, administrative and financial oversight; (Aim 2) communication links between projects and cores, corporate partners, the NIH, and external collaborators/advisors; (Aim 3) data management and security across the Center; (Aim 4) the management structure needed to review research progress, identify problems, periodically review targets, and prioritize hits and leads for further development; and (Aim 5) pilot and mentored award management. In addition, Adman Core A will accelerate drug development and build capacity through the open sharing of reagents, tools, assays, and models that catalyze robust in vitro and in vivo assays for emerging viruses. Adman Core A manages a diverse team of academic and industry partners with deep expertise in antiviral drug discovery from multiple fields, including virologists, biochemists, structural biologists, enzymologists, pharmacologists, modelers, and medicinal chemists. Importantly, Adman Core A also engages pharmaceutical leaders, specifically Takeda, J&J, Chimerix, and Pardes Biosciences, who contribute in-kind resources, assays, chemical assets, chemistry, expertise, and leadership. The program takes an innovative approach to drug development that includes an early open science platform as promoted by the Structural Genomics Consortium, but then transitions to encourage intellectual property protection of chemical assets being formulated for preIND and IND enabling studies. By leveraging the combined assets and resources of our corporate and academic partners, Adman Core A’s overall goal is to advance at least 2 DAA drugs to the milestone of a pre-IND meeting with the FDA